The story of Sildenafil presents a intricate picture for shareholders. While the initial introduction generated substantial returns, the lapse of its exclusive rights opened the door to generic alternatives, https://freebookmarkpost.com/story21488870/the-copyright-and-big-pharma-a-volatile-bet